Ovarian cancer
Conditions
Interventions
PARPi maintenance therapy for patients with recurrent ovarian cancer:None
PARPi maintains patients with treatment-sensitive ovarian cancer:None
Sponsors
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Newly diagnosed FIGO stage III–IV high-grade serous carcinoma, endometrioid carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma; 2.Patients experiencing their first recurrence of ovarian cancer or platinum-sensitive recurrence (PSR) during first-line PARP inhibitor (PARPi) maintenance therapy; 3.Presence of gBRCA1/2m, sBRCA1/2m, or non-BRCA1/2m homologous recombination deficiency (HRD); 4.Primary debulking surgery (PDS) performed at the enrolling institution, with well-preserved clinical data and pathological specimens; 5.Achieved complete response (CR) or partial response (PR) based on RECIST 1.1 criteria following postoperative platinum-based chemotherapy. 6. NACT is not used.
Exclusion criteria
Exclusion criteria: 1.Pathologically confirmed non-high-grade serous carcinoma, endometrioid carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma; 2.Lacking complete clinical data and pathological specimens. 3. NACT is used.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CA125 levels;2-year progression-free survival PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| More than 2 years progression-free survival (PFS) ;Identify clinical and/or molecular features associated with PARPi treatment outcomes;More than 2 yearsoverall survival (OS); | — |
Countries
China
Contacts
Public ContactXipeng Wang
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed